Phio Pharmaceuticals Corp.

NasdaqCM:PHIO Stock Report

Market Cap: US$1.9m

Phio Pharmaceuticals Management

Management criteria checks 2/4

Phio Pharmaceuticals' CEO is Bob Bitterman, appointed in Feb 2023, has a tenure of 1.83 years. total yearly compensation is $437.89K, comprised of 86.8% salary and 13.2% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $3.03K. The average tenure of the management team and the board of directors is 1.6 years and 7.5 years respectively.

Key information

Bob Bitterman

Chief executive officer

US$437.9k

Total compensation

CEO salary percentage86.8%
CEO tenure1.8yrs
CEO ownership0.2%
Management average tenure1.6yrs
Board average tenure7.5yrs

Recent management updates

Recent updates

Phio Pharmaceuticals appoints interim executive chairman

Sep 29

Phio Pharmaceuticals GAAP EPS of -$0.19 beats by $0.12

Aug 11

Is Phio Pharmaceuticals (NASDAQ:PHIO) In A Good Position To Deliver On Growth Plans?

Apr 11
Is Phio Pharmaceuticals (NASDAQ:PHIO) In A Good Position To Deliver On Growth Plans?

Phio soars 22% on positive in vivo data on combination PD-1 and TIGIT therapy in cancer

Nov 09

CEO Compensation Analysis

How has Bob Bitterman's remuneration changed compared to Phio Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$7m

Jun 30 2024n/an/a

-US$9m

Mar 31 2024n/an/a

-US$9m

Dec 31 2023US$438kUS$380k

-US$11m

Sep 30 2023n/an/a

-US$12m

Jun 30 2023n/an/a

-US$12m

Mar 31 2023n/an/a

-US$12m

Dec 31 2022US$173kUS$32k

-US$11m

Sep 30 2022n/an/a

-US$12m

Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$78kn/a

-US$13m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$10m

Dec 31 2020US$45kn/a

-US$9m

Sep 30 2020n/an/a

-US$9m

Jun 30 2020n/an/a

-US$9m

Mar 31 2020n/an/a

-US$9m

Dec 31 2019US$64kn/a

-US$9m

Sep 30 2019n/an/a

-US$8m

Jun 30 2019n/an/a

-US$7m

Mar 31 2019n/an/a

-US$7m

Dec 31 2018US$53kn/a

-US$7m

Sep 30 2018n/an/a

-US$8m

Jun 30 2018n/an/a

-US$9m

Mar 31 2018n/an/a

-US$9m

Dec 31 2017US$36kn/a

-US$12m

Compensation vs Market: Bob's total compensation ($USD437.89K) is below average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Bob's compensation has increased whilst the company is unprofitable.

CEO

Bob Bitterman (73 yo)

1.8yrs

Tenure

US$437,892

Compensation

Mr. Robert J. Bitterman, also known as Bob, serves as Chairman at Phio Pharmaceuticals Corp. since 2012 and President and Chief Executive Officer since February 20, 2023. Mr. Bitterman served as the Interi...

Leadership Team

NamePositionTenureCompensationOwnership
Robert Bitterman
President1.8yrsUS$437.89k0.16%
$ 3.0k
Robert Infarinato
CFO & Principal Accounting Officerless than a yearno datano data
Linda Mahoney
Senior Vice President of Development1.6yrsno datano data
Caitlin Kontulis
Secretaryno datano data0.061%
$ 1.1k

1.6yrs

Average Tenure

73yo

Average Age

Experienced Management: PHIO's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Robert Bitterman
President12.5yrsUS$437.89k0.16%
$ 3.0k
Patricia Bradford
Independent Director2.7yrsUS$57.86k0.033%
$ 619.6
Curtis Lockshin
Independent Director11.7yrsUS$50.36k0.034%
$ 626.6
Robert Ferrara
Lead Independent Director5.2yrsUS$70.36k0.042%
$ 783.2
Jonathan Freeman
Independent Director7.5yrsUS$42.86k0.034%
$ 626.6

7.5yrs

Average Tenure

73yo

Average Age

Experienced Board: PHIO's board of directors are considered experienced (7.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 12:45
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Phio Pharmaceuticals Corp. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Maxim JacobsEdison Investment Research
Mark BreidenbachH.C. Wainwright & Co.
Vernon BernardinoH.C. Wainwright & Co.